BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31925916)

  • 21. Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Rabin KR
    JAMA Oncol; 2020 Mar; 6(3):333-334. PubMed ID: 31944218
    [No Abstract]   [Full Text] [Related]  

  • 22. Dasatinib plus chemotherapy to achieve full donor chimerism and complete molecular remission in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Tamamyan G; Chao YH; Wang CH; Wu HP; Weng T; Peng CT; Wu KH
    Pediatr Blood Cancer; 2013 Oct; 60(10):1727-8. PubMed ID: 23737095
    [No Abstract]   [Full Text] [Related]  

  • 23. Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone.
    Takata H; Ikebe T; Sasaki H; Miyazaki Y; Ohtsuka E; Saburi Y; Ogata M; Shirao K
    Intern Med; 2016; 55(9):1177-81. PubMed ID: 27150875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
    Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
    Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?
    Leonard JT; Stock W
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1913-1914. PubMed ID: 27634020
    [No Abstract]   [Full Text] [Related]  

  • 28. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
    Wong SF
    J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
    Short NJ; Kantarjian HM; Sasaki K; Ravandi F; Ko H; Cameron Yin C; Garcia-Manero G; Cortes JE; Garris R; O'Brien SM; Patel K; Khouri M; Thomas D; Jain N; Kadia TM; Daver NG; Benton CB; Issa GC; Konopleva M; Jabbour E
    Am J Hematol; 2017 Mar; 92(3):238-243. PubMed ID: 28006851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Satake A; Okada M; Asada T; Fujita K; Ikegame K; Tamaki H; Fujimori Y; Ogawa H
    Leuk Lymphoma; 2010 Oct; 51(10):1920-2. PubMed ID: 20858093
    [No Abstract]   [Full Text] [Related]  

  • 33. [Sustained molecular remission with a tyrosine kinase inhibitor alone for seven months in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Takahashi T; Shigeoka T; Suzukawa M; Ishido A; Tominaga T
    Rinsho Ketsueki; 2013 Feb; 54(2):210-3. PubMed ID: 23470829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
    Santos FP; Cortes J
    Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
    Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
    [No Abstract]   [Full Text] [Related]  

  • 39. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Hematology Am Soc Hematol Educ Program; 2011; 2011():231-7. PubMed ID: 22160039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.